KRIBIOLISA Anti-Tenecteplase (TNKASE METALYSE) ELISA
KRIBIOLISA Anti-Tenecteplase (TNKase/Metalyse) ELISA
- Product Specifications
Tenecteplase is a fibrin-specific tissue-plasminogen activator. It binds to fibrin rich clots and cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.
Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
FDA has approved Tenecteplase as one of the protein based therapies classified under thrombolytic agents. Commercially it is available as a drug under the trade name TNKase™ from Roche and Metalyse™ from BoehringerIngelheim.
Safety considerations in the development of biologics are an important focus of regulatory guidelines. One of the major challenges is the immunogenicity profiling of these biologics. The potential risk of the patient developing an immune reaction during dosage regimen is to be assessed in detail.
|Other Specifications||Precoated plates using monoclonal antibodies; Sample type - Serum, plasma|
|Reactivity or Species||Human|
|Storage Condition||2-8 Deg C|
|Usage||For Research Use Only|